Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Monday

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) is expected to be posting its Q4 2024 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Avalo Therapeutics to post earnings of ($1.07) per share for the quarter.

Avalo Therapeutics Stock Down 6.7 %

Shares of Avalo Therapeutics stock traded down $0.29 on Friday, reaching $4.06. 35,662 shares of the company traded hands, compared to its average volume of 53,018. The company has a 50 day moving average of $6.14 and a 200 day moving average of $8.16. Avalo Therapeutics has a 52 week low of $4.06 and a 52 week high of $16.00.

Analyst Ratings Changes

A number of research firms have issued reports on AVTX. HC Wainwright reissued a "neutral" rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Stifel Nicolaus initiated coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a "buy" rating and a $36.00 price objective on the stock. Piper Sandler assumed coverage on shares of Avalo Therapeutics in a report on Friday, February 28th. They set an "overweight" rating and a $48.00 price objective on the stock. Wedbush reiterated an "outperform" rating and issued a $18.00 target price on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Finally, Jefferies Financial Group initiated coverage on shares of Avalo Therapeutics in a research note on Tuesday, March 25th. They set a "buy" rating and a $23.00 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $33.00.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.